As of March 13, when the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued its Case List update, 320 claims had been centralized in the California proceeding (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452). These 414 product liability claims are currently pending in a federal multidistrict litigation (MDL) taking place in U.S. District Court, Southern District of California.
Plaintiffs allege that the diabetes drugs caused pancreatic cancer, as well as pancreatitis and thyroid cancer.
Diabetes spells big profits for Merck & Co., the Januvia manufacturer, so much so that Januvia settlements are just a drop in the money bucket for the giant drug company.
The FDA approved Sitagliptin, sold under the name Januvia, in 2006, and just six years later, it was being investigated for a potential cancer risk. Merck even admits that its drug has serious side effects, including low blood sugar, allergic reactions (including Stevens Johnson Syndrome) and life-threatening anaphylaxis, acute pancreatitis and death. It falls short of listing cancer.
READ MORE JANUVIA LEGAL NEWS
Dr. Mercola is convinced that Januvia is linked to cancer. He believes the only reason it is still on the market is because billions of dollars are at stake for Merck; Januvia is the best-selling drug to treat diabetes. Watch his video here.